Glovadalen, a novel D1 receptor positive allosteric modulator, is linked to improve OFF time in patients with Parkinson’s ...

Neurocrine Biosciences has penned a deal with China’s TransThera Sciences potentially worth more than $880 million in ...

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 29, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ...

Please provide your email address to receive an email when new articles are posted on . Change from baseline in gait variability did not differ between groups, regardless of cognitive load. Treatment ...

Tempero Bio has hit the brakes on a phase 2-stage alcohol use disorder (AUD) candidate while the biotech considers its options, according to the program’s partner. | Tempero Bio has hit the brakes on ...

Ivana Magovčević-Liebisch President and CEO, Dr Magovčević-Liebisch is an accomplished pharmaceutical and biotechnology ...

Please provide your email address to receive an email when new articles are posted on . A Swiss biopharmaceutical company announced its launch with $63 million in Series A financing for research and ...

NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora’s M4 franchise; both programs have potential best-in-class ...

Geneva, Switzerland and New York, USA, April 3, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company pioneering allosteric modulation-based drug development, ...

Topline results were announced from a phase 3 trial evaluating BNC210 in patients with social anxiety disorder.